Take 2 Prophecy™
Nasopharyngeal Carcinoma (NPC) is a prevalent malignant tumor in Hong Kong and Southern China. Due to its hidden anatomical location, early-stage NPC often presents with subtle or non-specific symptoms. Developed by top university genetic research teams in Hong Kong, Take 2 Prophecy™ leverages Next-Generation Sequencing (NGS) to analyze plasma EBV DNA with a proven accuracy of up to 97%. A simple blood test delivers highly precise, non-invasive early NPC risk identification, with official results available within 3 to 7 working days.
$1,800
Monday to Friday：9 am – 6 pm
Saturday：9 am – 1 pm
Sunday and Public Holiday：Closed
We can upload images to eHRSS.
We support the use of Health Care Voucher.
The test utilises the NGS technology invented by the team from The Chinese University of Hong Kong(CUHK).
Only requires a single blood draw. It enables NPC patients to be identified in their early stage for timely treatment and increases their survival rate.
